Completed PHASE4 INTERVENTIONAL 2-arm NCT05218915

Basal Plus GLP1-ra on Glycemic Variability in CKD

Effect of Glucagon-like Peptide 1 Receptor Agonist in Combination with Insulin on Glycaemic Variability and Time-in-range in Diabetic Kidney Disease: a Randomised Controlled Trial

Sponsor: Elaine Chow

Conditions Diabetes Mellitus Diabetic Kidney Disease

Interventions Continuous glucose monitor Dulaglutide Insulin Degludec

Updated 6 times since 2022 Last updated: Nov 29, 2024 Started: Jan 28, 2022 Primary completion: Oct 30, 2024 Completion: Oct 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Diabetes Mellitus and Diabetic Kidney Disease, this trial is completed. The trial is conducted by Elaine Chow and has accumulated 6 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Jan 2025 — Sep 2025 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Dec 2022 — Jul 2024 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2022 — Dec 2022 [monthly]

Not Yet Recruiting PHASE4

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Elaine Chow

Data source: Chinese University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shatin, Hong Kong